Literature DB >> 11376414

Predicting axillary nodal positivity in 2282 patients with breast carcinoma.

M J Silverstein1, K A Skinner, T J Lomis.   

Abstract

Axillary lymph node status continues to be the single most important prognostic variable for breast cancer survival despite significant progress in the molecular and genetic characterization of breast malignancies. All patients with invasive breast cancer who underwent axillary lymph node dissection as part of their treatment were evaluated by 11 clinical and pathologic factors, including the primary lesion's T category (TNM staging system), whether the lesion was clinically palpable, the presence of lymphatic or vascular invasion, nuclear grade, estrogen and progesterone receptors, S-phase, age, HER2/neu overexpression, histology (infiltrating lobular or ductal), and ploidy. A total of 2282 axillary dissections were performed: 391 in patients with ductal carcinoma in situ (DCIS) [3 of which (0.8%) contained metastases] and 1891 in patients with invasive breast cancer [680 of which (36%) contained metastases]. Multivariate analysis of patients with invasive cancer identified four factors as independent predictors of axillary lymph node metastases: lymph/vascular invasion, tumor size, nuclear grade, tumor palpability. Among a group of 189 patients with nonpalpable, non-high-grade invasive lesions 15 mm or smaller without lymph/vascular invasion, only 6 (3%) had metastases to lymph nodes. If any three of the favorable factors were present, lymph node positivity was 6% or less. Clinical and pathologic feature of the primary lesions can be used to estimate the risk of axillary lymph node metastases. Such risk assessment can be used for the treatment decision-making process.

Entities:  

Mesh:

Year:  2001        PMID: 11376414     DOI: 10.1007/s00268-001-0003-x

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  41 in total

1.  [Sentinel lymph node biopsy in breast cancer].

Authors:  A Rody; C Solbach; M Kaufmann
Journal:  Chirurg       Date:  2004-08       Impact factor: 0.955

2.  Results of preoperative lymphoscintigraphy for breast cancer are predictive of identification of axillary sentinel lymph nodes.

Authors:  Frédéric Marchal; Philippe Rauch; Olivier Morel; Jean Claude Mayer; Pierre Olivier; Agnès Leroux; Jean Luc Verhaeghe; François Guillemin
Journal:  World J Surg       Date:  2006-01       Impact factor: 3.352

Review 3.  A nodal positivity constant: new perspectives in lymph node evaluation and colorectal cancer.

Authors:  Niamh M Hogan; Desmond C Winter
Journal:  World J Surg       Date:  2013-04       Impact factor: 3.352

4.  Mortality and recurrence patterns of breast cancer patients diagnosed under a screening programme versus comparable non-screened breast cancer patients from the same population: analytical survey from 2002 to 2012.

Authors:  A García Fernández; C Chabrera; M García Font; M Fraile; J M Lain; S Gónzalez; C Corral; M Torras; J Torres; M Teixido; I Barco; R López; C Gónzalez; A Pessarrodona; N Giménez
Journal:  Tumour Biol       Date:  2013-10-09

5.  Predictors of axillary lymph node metastases (ALNM) in a Korean population with T1-2 breast carcinoma: triple negative breast cancer has a high incidence of ALNM irrespective of the tumor size.

Authors:  Jong Hoon Lee; Sung Hwan Kim; Young Jin Suh; Byoung Yong Shim; Hoon Kyo Kim
Journal:  Cancer Res Treat       Date:  2010-03-31       Impact factor: 4.679

6.  Correlation between serum levels of vascular endothelial growth factor-C and sentinel lymph node status in early breast cancer.

Authors:  Diego Pérez; Alexander Rohde; Gonzalo Callejón; Elisabeth Pérez-Ruiz; Isabel Rodrigo; Francisco Rivas-Ruiz; Belen Ramos; Francisco Medina; Rosa Villatoro; Maximino Redondo; Irene Zarcos; Claudio Maañón; Antonio Rueda
Journal:  Tumour Biol       Date:  2015-06-24

7.  Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Authors:  Karla Kerlikowske; Annette M Molinaro; Mona L Gauthier; Hal K Berman; Fred Waldman; James Bennington; Henry Sanchez; Cynthia Jimenez; Kim Stewart; Karen Chew; Britt-Marie Ljung; Thea D Tlsty
Journal:  J Natl Cancer Inst       Date:  2010-04-28       Impact factor: 13.506

8.  Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome.

Authors:  Benjamin D L Li; Jeffrey S Gruner; Fleurette Abreo; Lester W Johnson; Herbert Yu; Soheir Nawas; John C McDonald; Arrigo DeBenedetti
Journal:  Ann Surg       Date:  2002-05       Impact factor: 12.969

9.  A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer.

Authors:  Derek R McClusky; Quyen Chu; Herbert Yu; Arrigo Debenedetti; Lester W Johnson; Carol Meschonat; Richard Turnage; John C McDonald; Fleurette Abreo; Benjamin D L Li
Journal:  Ann Surg       Date:  2005-10       Impact factor: 12.969

10.  A Comparison of the Proteomic Expression in Pooled Saliva Specimens from Individuals Diagnosed with Ductal Carcinoma of the Breast with and without Lymph Node Involvement.

Authors:  Charles F Streckfus; Karen A Storthz; Lenora Bigler; William P Dubinsky
Journal:  J Oncol       Date:  2009-12-20       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.